FDA Guts Fish Oil Pills’ Reg Strategy: Nixes Longer Exclusivity For Vascepa, Revised Listing For Lovaza
This article was originally published in The Pink Sheet Daily
Amarin says it may challenge FDA’s decision on Vascepa exclusivity; Crowell & Moring had wanted a reduced dose of Lovaza listed in the Orange Book.
You may also be interested in...
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.
FTC and DoJ issue guidance for businesses working together to tackle coronavirus pandemic; BIO is 'pleased' they intend to help facilitate critical partnerships.
Teva and US FDA disagree over whether Copaxone is a protein. While generics are already on the market, Teva wants to assert process patents against future would-be competitors, which the firm cannot do through the ANDA pathway.